CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 260 enrolled
Drug / intervention
Omega Three Polyunsaturated fatty acidsdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00446966
NCT00446966Phase 4Completed

Fish Oil to Inhibit Supraventricular Arrhythmias After Cardiac Surgery: The Fish Trial

Chirag Sandesara·interventional·Posted Mar 13, 2007·Updated Oct 10, 2018

In Brief

A Phase 4 clinical trial evaluating Omega Three Polyunsaturated fatty acids for Atrial Fibrillation. Completed, enrolled 260 participants across 1 site.

Detailed Summary

The primary objective of this study is to determine if omega-3 polyunsaturated fatty acids reduce atrial fibrillation and other outcomes after cardiac surgery. In this placebo-controlled trial, patients undergoing elective coronary artery bypass graft surgery with or without valve repair will be treated with omega-3 polyunsaturated fatty acids perioperatively. The following hypotheses will be tested: 1. omega-3 polyunsaturated fatty acids reduces the incidence of atrial fibrillation (AF) after cardiac surgery, 2. omega-3 polyunsaturated fatty acids, administered in the perioperative period for cardiac surgery, decreases postoperative complication rates, and 3. omega-3 polyunsaturated fatty acids decrease intensive care unit and hospital length-of-stay.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
CollaboratorsGlaxoSmithKline

Timeline

Phase 4CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMar 13, 2007
Enrollment StartFeb 1, 2007
Primary CompletionDec 1, 2009
Study CompletionJan 1, 2010
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 19.3 years ago

Interventions

Omega Three Polyunsaturated fatty acidsdrug

2 grams orally twice daily pre-operatively and 2 grams orally daily after until primary endpoint or 14 days.